Current choice of treatments for neovascular AMD. Issue 1 (January 2014)

• Record Type: Journal Article
• Authors: Lai, Kevin; Landa, Gennady
• Is Part Of: Expert review of clinical pharmacology. Volume 8:Issue 1(2015)
• Page Start: 135
• Page End: 140
• Publication Date: 2014-01
• Subjects: Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1586/17512433.2015.990379
• Languages: English
• ISSNs: 1751-2433

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Age-related macular degeneration is the leading cause of irreversible blindness in developed countries with the neovascular form accounting for the majority of severe vision loss in the disease. The management of wet age-related macular degeneration has improved drastically in the past decade as anti-VEGF agents took its place at the forefront of treatment. As the choice of therapy is based on a number of factors, this review summarizes the pivotal studies that brought these agents to use and compares the different agents currently available. This review also briefly describes the promising new therapies that are in development.</p> </abstract>